Pages
- 2021 Convention Photos
- 2022 Conference Photos
- 2023 Convention Photos
- About us
- AQCAMO
- Become a member of AQCAMO
- Conference 2025 Photos
- Conferences and partner capsules
- Conferences During the Congress
- Congress 2024 Photos
- Contact us
- Edit my profile
- Events
- Frequently asked questions
- Insurance companies
- Member dashboard
- News
- No access
- Partners
- Privacy policy
- Reimbursement
- Role of the Drug Access Navigators CAMs-DANs
- Site map
- Support
- Terms and conditions of use
- Useful links
- Webinars
Posts by category
- Category: Events
- Category: News
- Pembrolizumab (Keytruda)
- Pembrolizumab (Keytruda):
- Pembrolizumab (Keytruda):
- BLENREP (belantamab mafodotin)
- Lanreotide (MYTOLAC)
- ACALABRUTINIB & VENETOCLAX IN COMBINATION:
- Encorafenib: Braftovi
- Tarlatamab (Imdelltra)
- LANREOTIDE (LANULINE AUTOGEL)
- ENHERTU
- ENHERTU
- Durvalumab (IMFINZI)
- BLENREP (BELANTAMAB MAFODOTIN)
- Pembrolizumab Keytruda
- Pembrolizumab Keytruda
- Pembrolizumab Keytruda
- PEMAZYRE® (pemigatinib)
- VANFLYTA (quizartinib)
- Osimertinib(Tagrisso)
- PrKEYTRUDA® (pembrolizumab)
- Truqap (capivasertib)
- ZOLADEX® LA (10.8 mg) in breast cancer
- Scemblix® (asciminib)
- Scemblix® (asciminib)
- PrKEYTRUDA® (pembrolizumab)
- NUBEQA (darolutamide)
- OPDIVO® + YERVOY® New Patient Support Programs from Bristol Myers Squibb Canada
- New Time-Limited Patient Support Program for Encorafenib (BRAFTOVI)
- Durvalumab (Imfinzi): Muscle-invasive bladder cancer (MIBC)
- KEYTRUDA® (Pembrolizumab)
- LAZCLUZE® (Lazertinib)
- AstraZeneca Canada will discontinue the free drug access component of the PSP for all NEW patients enrolled after March 31, 2025.
- Durvalumab (Imfinzi)
- Enhertu (Trastuzumab Deruxtecan)
- Pembrolizumab (Keytruda) New indication
- Category: Non catégorisé
